[{"id":"110cd83b-a31c-4b26-8b05-9ad93be67a86","acronym":"","url":"https://clinicaltrials.gov/study/NCT04530565","created_at":"2021-01-18T21:41:29.599Z","updated_at":"2025-02-25T14:07:51.985Z","phase":"Phase 3","brief_title":"Testing the Use of Steroids and Tyrosine Kinase Inhibitors With Blinatumomab or Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in Adults","source_id_and_acronym":"NCT04530565","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" ABL1 • BCR","pipe":" | ","alterations":" ABL1 T315I","tags":["ABL1 • BCR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ABL1 T315I"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e dasatinib • cytarabine • Iclusig (ponatinib) • doxorubicin hydrochloride • cyclophosphamide • Blincyto (blinatumomab) • methotrexate • vincristine • prednisone • dexamethasone • mesna • Hemady (dexamethasone tablets) • Starasid (cytarabine ocfosfate) • cyclophosphamide intravenous • dexamethasone injection"],"overall_status":"Recruiting","enrollment":" Enrollment 348","initiation":"Initiation: 01/25/2021","start_date":" 01/25/2021","primary_txt":" Primary completion: 07/01/2028","primary_completion_date":" 07/01/2028","study_txt":" Completion: 07/01/2028","study_completion_date":" 07/01/2028","last_update_posted":"2025-02-19"},{"id":"825e707d-d24d-4a05-b786-1228f5cc02ad","acronym":"Window-2","url":"https://clinicaltrials.gov/study/NCT03710772","created_at":"2021-01-18T18:11:30.804Z","updated_at":"2025-02-25T15:34:12.058Z","phase":"Phase 2","brief_title":"Ibrutinib, Rituximab, Venetoclax, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma","source_id_and_acronym":"NCT03710772 - Window-2","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" TP53 • CD20 • NSD2","pipe":" | ","alterations":" TP53 mutation • CD20 positive","tags":["TP53 • CD20 • NSD2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • CD20 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • Imbruvica (ibrutinib) • Rituxan (rituximab) • cytarabine • doxorubicin hydrochloride • cyclophosphamide • methotrexate • vincristine • dexamethasone • Truxima (rituximab-abbs) • Riabni (rituximab-arrx) • Delito (rituximab biosimilar) • GB241 (rituximab biosimilar) • JHL1101 (rituximab biosimilar) • Novex (rituximab biosimilar) • SIBP-02 (rituximab biosimilar) • Starasid (cytarabine ocfosfate) • cyclophosphamide intravenous • dexamethasone injection • methotrexate IV"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 51","initiation":"Initiation: 05/01/2019","start_date":" 05/01/2019","primary_txt":" Primary completion: 05/22/2025","primary_completion_date":" 05/22/2025","study_txt":" Completion: 05/22/2025","study_completion_date":" 05/22/2025","last_update_posted":"2025-02-11"},{"id":"2aac339a-fbd4-48aa-9c04-5e7a6adc7234","acronym":"NCI-MATCH","url":"https://clinicaltrials.gov/study/NCT02465060","created_at":"2021-01-17T17:15:30.769Z","updated_at":"2025-02-25T16:36:36.993Z","phase":"Phase 2","brief_title":"Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)","source_id_and_acronym":"NCT02465060 - NCI-MATCH","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" MSI • CD4","pipe":" | ","alterations":" PD-L1 expression","tags":["MSI • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Opdivo (nivolumab) • Avastin (bevacizumab) • Herceptin (trastuzumab) • Lynparza (olaparib) • Mekinist (trametinib) • cisplatin • Xalkori (crizotinib) • Tagrisso (osimertinib) • Tecentriq (atezolizumab) • Gilotrif (afatinib) • Yervoy (ipilimumab) • Ibrance (palbociclib) • dasatinib • Tafinlar (dabrafenib) • carboplatin • Imfinzi (durvalumab) • Vitrakvi (larotrectinib) • Imbruvica (ibrutinib) • gemcitabine • paclitaxel • Rituxan (rituximab) • docetaxel • 5-fluorouracil • sunitinib • everolimus • Vectibix (panitumumab) • temozolomide • Koselugo (selumetinib) • Perjeta (pertuzumab) • cytarabine • Kadcyla (ado-trastuzumab emtansine) • bortezomib • doxorubicin hydrochloride • Talzenna (talazoparib) • capecitabine • Piqray (alpelisib) • Xtandi (enzalutamide) • azacitidine • Cabometyx (cabozantinib tablet) • Balversa (erdafitinib) • Gazyva (obinutuzumab) • Mektovi (binimetinib) • albumin-bound paclitaxel • cyclophosphamide • Imjudo (tremelimumab-actl) • Cyramza (ramucirumab) • pemetrexed • fulvestrant • oxaliplatin • adavosertib (AZD1775) • etoposide IV • irinotecan • Halaven (eribulin mesylate) • Xpovio (selinexor) • Conmana (icotinib) • Pemazyre (pemigatinib) • Truqap (capivasertib) • methotrexate • Zarnestra (tipifarnib) • Aliqopa (copanlisib) • fexagratinib (ABSK091) • Ninlaro (ixazomib) • pegylated liposomal doxorubicin • epirubicin • sapanisertib (CB-228) • ipatasertib (RG7440) • Caprelsa (vandetanib) • vincristine • vinorelbine tartrate • Cometriq (cabozantinib capsule) • Tabrecta (capmatinib) • spartalizumab (PDR001) • taselisib (GDC-0032) • daunorubicin • omipalisib (GSK2126458) • ulixertinib (BVD-523) • mitoxantrone • Erivedge (vismodegib) • carmustine • bendamustine • bicalutamide • leucovorin calcium • Mvasi (bevacizumab-awwb) • Vegzelma (bevacizumab-adcd) • Zepzelca (lurbinectedin) • mitomycin • Jingzhuda (entinostat) • Recentin (cediranib) • Trazimera (trastuzumab-qyyp) • melphalan • Fakzynja (defactinib) • GSK2636771 • Zirabev (bevacizumab-bvzr) • goserelin acetate • Zynyz (retifanlimab-dlwr) • fludarabine IV • Ostarine (enobosarm) • avadomide (CC-122) • vistusertib (AZD2014) • Myocet (non-pegylated liposomal doxorubicin) • mesna • vinblastine • Xofigo (radium Ra-223 dichloride) • lorvotuzumab mertansine (IMGN901) • Ampligen (rintatolimod) • E6201 • Fujovee (abivertinib) • Paletan (pertuzumab biosimilar) • Provenge (sipuleucel-T) • relatlimab (BMS-986016) • ABP 206 (nivolumab biosimilar) • Airuituo (bevacizumab biosimilar) • Beianting (bevacizumab biosimilar) • Boyounuo (bevacizumab biosimilar) • CC-90002 • EG1206A (pertuzumab biosimilar) • GB222 (bevacizumab biosimilar) • Hanbeitai (bevacizumab biosimilar) • ImmuniCell (autologous γδ T lymphocytes) • Leukine (sargramostim) • Pertuvia (pertuzumab biosimilar) • Vasforda (bevacizumab biosimilar) • celecoxib oral • cyclophosphamide intravenous • dexamethasone injection • ieramilimab (LAG525) • levoleucovorin calcium • methotrexate IV • sapitinib (AZD8931)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 6452","initiation":"Initiation: 08/17/2015","start_date":" 08/17/2015","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2025-02-06"},{"id":"a5f14953-ab61-4581-b513-a86ad8a1e2b8","acronym":"AALL0434","url":"https://clinicaltrials.gov/study/NCT00408005","created_at":"2021-01-17T17:29:32.376Z","updated_at":"2025-02-25T16:50:52.092Z","phase":"Phase 3","brief_title":"Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma","source_id_and_acronym":"NCT00408005 - AALL0434","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD20 • CD8 • CD22 • CD34 • CD5 • CD7 • CD2 • MPO","pipe":" | ","alterations":" CD22 expression","tags":["CD20 • CD8 • CD22 • CD34 • CD5 • CD7 • CD2 • MPO"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD22 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • doxorubicin hydrochloride • cyclophosphamide • methotrexate • vincristine • daunorubicin • dexamethasone • leucovorin calcium • Oncaspar liquid (pegaspargase) • mercaptopurine delayed release (DR6MP) • nelarabine • mercaptopurine • thioguanine • Hemady (dexamethasone tablets) • Kidrolase (L-asparaginase) • Leunase (L-asparaginase) • Spectrila (asparaginase Escherichia coli) • Starasid (cytarabine ocfosfate) • cyclophosphamide intravenous • dexamethasone injection"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 1895","initiation":"Initiation: 01/22/2007","start_date":" 01/22/2007","primary_txt":" Primary completion: 09/30/2017","primary_completion_date":" 09/30/2017","study_txt":" Completion: 03/07/2025","study_completion_date":" 03/07/2025","last_update_posted":"2025-02-04"},{"id":"90e00a6d-bf2f-470b-9aff-9a2babcf60e1","acronym":"SWOG-S1304","url":"https://clinicaltrials.gov/study/NCT01903811","created_at":"2025-02-26T08:59:23.400Z","updated_at":"2025-02-26T08:59:23.400Z","phase":"Phase 2","brief_title":"S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma","source_id_and_acronym":"NCT01903811 - SWOG-S1304","lead_sponsor":"SWOG Cancer Research Network","biomarkers":" CRP","pipe":"","alterations":" ","tags":["CRP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carfilzomib • dexamethasone injection"],"overall_status":"Completed","enrollment":" Enrollment 143","initiation":"Initiation: 10/01/2013","start_date":" 10/01/2013","primary_txt":" Primary completion: 11/21/2017","primary_completion_date":" 11/21/2017","study_txt":" Completion: 03/07/2019","study_completion_date":" 03/07/2019","last_update_posted":"2024-12-20"},{"id":"6c8187f2-a1a7-4e0d-9839-99324cab5154","acronym":"","url":"https://clinicaltrials.gov/study/NCT06022939","created_at":"2023-09-05T18:12:25.015Z","updated_at":"2024-07-02T16:34:27.373Z","phase":"Phase 3","brief_title":"Comparing Dara-VCD Chemotherapy Plus Stem Cell Transplant to Dara-VCD Chemotherapy Alone for People Who Have Newly Diagnosed AL Amyloidosis","source_id_and_acronym":"NCT06022939","lead_sponsor":"SWOG Cancer Research Network","biomarkers":" CD34","pipe":" | ","alterations":" Chr t(11;14)","tags":["CD34"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Chr t(11;14)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e bortezomib • cyclophosphamide • melphalan • Darzalex Faspro (daratumumab and hyaluronidase-fihj) • Hemady (dexamethasone tablets) • dexamethasone injection"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 338","initiation":"Initiation: 07/01/2024","start_date":" 07/01/2024","primary_txt":" Primary completion: 07/29/2030","primary_completion_date":" 07/29/2030","study_txt":" Completion: 10/29/2030","study_completion_date":" 10/29/2030","last_update_posted":"2024-06-11"},{"id":"8e23dfed-66db-4dea-b013-38aff34edc35","acronym":"NCI-2015-00960","url":"https://clinicaltrials.gov/study/NCT02427620","created_at":"2021-01-17T17:51:13.234Z","updated_at":"2024-07-02T16:34:36.739Z","phase":"Phase 2","brief_title":"Ibrutinib, Rituximab, and Consolidation Chemotherapy in Treating Young Patients With Newly Diagnosed Mantle Cell Lymphoma","source_id_and_acronym":"NCT02427620 - NCI-2015-00960","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" TP53 • MYC • CD20","pipe":" | ","alterations":" TP53 mutation • CD20 positive","tags":["TP53 • MYC • CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • CD20 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imbruvica (ibrutinib) • Rituxan (rituximab) • cytarabine • doxorubicin hydrochloride • cyclophosphamide • methotrexate • vincristine • daunorubicin • dexamethasone • Truxima (rituximab-abbs) • Riabni (rituximab-arrx) • Delito (rituximab biosimilar) • Hemady (dexamethasone tablets) • GB241 (rituximab biosimilar) • Novex (rituximab biosimilar) • Starasid (cytarabine ocfosfate) • cyclophosphamide intravenous • dexamethasone injection • methotrexate IV"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 131","initiation":"Initiation: 06/03/2015","start_date":" 06/03/2015","primary_txt":" Primary completion: 06/30/2025","primary_completion_date":" 06/30/2025","study_txt":" Completion: 06/30/2025","study_completion_date":" 06/30/2025","last_update_posted":"2024-06-10"},{"id":"9bdad34e-56d0-48b9-af40-2c4c90d60427","acronym":"WP42004","url":"https://clinicaltrials.gov/study/NCT04580121","created_at":"2021-06-30T14:53:56.262Z","updated_at":"2024-07-02T16:34:59.484Z","phase":"Phase 1","brief_title":"A Dose Escalation and Expansion Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7283420.","source_id_and_acronym":"NCT04580121 - WP42004","lead_sponsor":"Hoffmann-La Roche","biomarkers":" HLA-A","pipe":" | ","alterations":" HLA-A*02","tags":["HLA-A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HLA-A*02"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e dasatinib • Actemra IV (tocilizumab) • RG6007 • dexamethasone injection"],"overall_status":"Completed","enrollment":" Enrollment 59","initiation":"Initiation: 11/04/2020","start_date":" 11/04/2020","primary_txt":" Primary completion: 08/09/2023","primary_completion_date":" 08/09/2023","study_txt":" Completion: 08/09/2023","study_completion_date":" 08/09/2023","last_update_posted":"2024-06-03"},{"id":"30181726-4a7a-4641-822a-3105dcd88382","acronym":"","url":"https://clinicaltrials.gov/study/NCT05303792","created_at":"2022-03-31T17:52:41.961Z","updated_at":"2024-07-02T16:35:01.827Z","phase":"Phase 2","brief_title":"Testing the Combination of Inotuzumab Ozogamicin and Lower Dose Chemotherapy Compared to Usual Chemotherapy for Adults With B-Cell Acute Lymphoblastic Leukemia or B-Cell Lymphoblastic Lymphoma","source_id_and_acronym":"NCT05303792","lead_sponsor":"Alliance for Clinical Trials in Oncology","biomarkers":" CD20 • CD22","pipe":" | ","alterations":" CD20 expression • CD22 positive","tags":["CD20 • CD22"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 expression • CD22 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • cytarabine • doxorubicin hydrochloride • cyclophosphamide • methotrexate • Besponsa (inotuzumab ozogamicin) • vincristine • prednisone • mercaptopurine • dexamethasone injection"],"overall_status":"Recruiting","enrollment":" Enrollment 66","initiation":"Initiation: 02/27/2023","start_date":" 02/27/2023","primary_txt":" Primary completion: 05/31/2025","primary_completion_date":" 05/31/2025","study_txt":" Completion: 05/01/2028","study_completion_date":" 05/01/2028","last_update_posted":"2024-05-23"},{"id":"cc43e353-d912-4b11-8947-43a4ef4b102a","acronym":"SINE","url":"https://clinicaltrials.gov/study/NCT02199665","created_at":"2021-01-18T10:17:08.750Z","updated_at":"2024-07-02T16:35:03.805Z","phase":"Phase 1","brief_title":"Selinexor, Carfilzomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma","source_id_and_acronym":"NCT02199665 - SINE","lead_sponsor":"University of Chicago","biomarkers":" CRBN","pipe":"","alterations":" ","tags":["CRBN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xpovio (selinexor) • carfilzomib • dexamethasone • dexamethasone injection"],"overall_status":"Recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 06/12/2014","start_date":" 06/12/2014","primary_txt":" Primary completion: 07/01/2024","primary_completion_date":" 07/01/2024","study_txt":" Completion: 12/25/2024","study_completion_date":" 12/25/2024","last_update_posted":"2024-05-14"},{"id":"8619bc98-1a57-45c6-ac5d-41c349363497","acronym":"AALL1821","url":"https://clinicaltrials.gov/study/NCT04546399","created_at":"2021-01-18T21:44:55.124Z","updated_at":"2024-07-02T16:35:08.952Z","phase":"Phase 2","brief_title":"A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)","source_id_and_acronym":"NCT04546399 - AALL1821","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD19","pipe":" | ","alterations":" CD19 expression","tags":["CD19"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • cytarabine • doxorubicin hydrochloride • cyclophosphamide • Blincyto (blinatumomab) • etoposide IV • methotrexate • vincristine • dexamethasone • leucovorin calcium • Oncaspar liquid (pegaspargase) • mercaptopurine delayed release (DR6MP) • mercaptopurine • thioguanine • Hemady (dexamethasone tablets) • Starasid (cytarabine ocfosfate) • cyclophosphamide intravenous • dexamethasone injection"],"overall_status":"Suspended","enrollment":" Enrollment 550","initiation":"Initiation: 12/04/2020","start_date":" 12/04/2020","primary_txt":" Primary completion: 06/30/2028","primary_completion_date":" 06/30/2028","study_txt":" Completion: 06/30/2028","study_completion_date":" 06/30/2028","last_update_posted":"2024-04-18"},{"id":"ec361a88-10be-462e-b8c7-8fa193d6a067","acronym":"","url":"https://clinicaltrials.gov/study/NCT03418038","created_at":"2021-01-18T16:51:47.082Z","updated_at":"2024-07-02T16:35:11.929Z","phase":"Phase 2","brief_title":"Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia","source_id_and_acronym":"NCT03418038","lead_sponsor":"Mayo Clinic","biomarkers":" IDH1 • BCL2 • IDH2 • DNMT3A • SF3B1 • TET2 • SRSF2 • U2AF1 • CD4 • ZRSR2","pipe":" | ","alterations":" IDH2 mutation • DNMT3A mutation • TET2 mutation • SF3B1 mutation • EZH2 mutation • SRSF2 mutation • U2AF1 mutation","tags":["IDH1 • BCL2 • IDH2 • DNMT3A • SF3B1 • TET2 • SRSF2 • U2AF1 • CD4 • ZRSR2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH2 mutation • DNMT3A mutation • TET2 mutation • SF3B1 mutation • EZH2 mutation • SRSF2 mutation • U2AF1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • carboplatin • gemcitabine • Rituxan (rituximab) • cytarabine • cyclophosphamide • ifosfamide • oxaliplatin • etoposide IV • decitabine • dexamethasone • Truxima (rituximab-abbs) • Riabni (rituximab-arrx) • Delito (rituximab biosimilar) • Hemady (dexamethasone tablets) • GB241 (rituximab biosimilar) • JHL1101 (rituximab biosimilar) • Mabtas (rituximab biosimilar) • Novex (rituximab biosimilar) • SIBP-02 (rituximab biosimilar) • Starasid (cytarabine ocfosfate) • cyclophosphamide intravenous • dexamethasone injection"],"overall_status":"Recruiting","enrollment":" Enrollment 80","initiation":"Initiation: 03/23/2018","start_date":" 03/23/2018","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 03/01/2026","study_completion_date":" 03/01/2026","last_update_posted":"2024-04-02"},{"id":"413fd329-dd85-45a6-b07c-a0fee98c2f35","acronym":"","url":"https://clinicaltrials.gov/study/NCT04743661","created_at":"2021-02-08T13:52:25.106Z","updated_at":"2024-07-02T16:35:12.204Z","phase":"Phase 2","brief_title":"131I-Omburtamab, in Recurrent Medulloblastoma and Ependymoma","source_id_and_acronym":"NCT04743661","lead_sponsor":"Pediatric Brain Tumor Consortium","biomarkers":" CD276","pipe":"","alterations":" ","tags":["CD276"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • temozolomide • irinotecan • Omblastys (131I-omburtamab) • dexamethasone injection • ondansetron intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 62","initiation":"Initiation: 04/04/2022","start_date":" 04/04/2022","primary_txt":" Primary completion: 10/30/2029","primary_completion_date":" 10/30/2029","study_txt":" Completion: 10/30/2030","study_completion_date":" 10/30/2030","last_update_posted":"2024-03-29"},{"id":"d5be950f-3675-484f-9cf0-33481c11c95d","acronym":"NCI-2011-03562","url":"https://clinicaltrials.gov/study/NCT01527149","created_at":"2021-01-18T06:26:25.305Z","updated_at":"2024-07-02T16:35:20.370Z","phase":"Phase 2","brief_title":"Ofatumumab in Combination With Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine Sulfate, and Dexamethasone Alternating With Ofatumumab in Combination With Cytarabine and Methotrexate in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma","source_id_and_acronym":"NCT01527149 - NCI-2011-03562","lead_sponsor":"Roswell Park Cancer Institute","biomarkers":" CD20 • CCND1 • IGH • CD5 • FCER2","pipe":" | ","alterations":" Chr t(11;14) • CD20 expression","tags":["CD20 • CCND1 • IGH • CD5 • FCER2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Chr t(11;14) • CD20 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • doxorubicin hydrochloride • cyclophosphamide • methotrexate • vincristine • dexamethasone • Arzerra (ofatumumab) • Starasid (cytarabine ocfosfate) • cyclophosphamide intravenous • dexamethasone injection • methotrexate IV"],"overall_status":"Completed","enrollment":" Enrollment 37","initiation":"Initiation: 12/06/2011","start_date":" 12/06/2011","primary_txt":" Primary completion: 04/26/2018","primary_completion_date":" 04/26/2018","study_txt":" Completion: 01/11/2024","study_completion_date":" 01/11/2024","last_update_posted":"2024-02-07"},{"id":"0b154df6-4ebb-42ce-a9c2-2bdabd8ac5fb","acronym":"","url":"https://clinicaltrials.gov/study/NCT06115135","created_at":"2023-11-02T15:13:03.515Z","updated_at":"2024-07-02T16:35:22.451Z","phase":"Phase 2","brief_title":"A Study of Venetoclax in Combination With Isatuximab and Dexamethasone for Relapsed/Refractory Multiple Myeloma","source_id_and_acronym":"NCT06115135","lead_sponsor":"Oncotherapeutics","biomarkers":" BCL2 • TNFA","pipe":" | ","alterations":" Chr t(11;14)","tags":["BCL2 • TNFA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Chr t(11;14)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • carfilzomib • Sarclisa (isatuximab-irfc) • dexamethasone injection"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 39","initiation":"Initiation: 03/01/2024","start_date":" 03/01/2024","primary_txt":" Primary completion: 03/31/2026","primary_completion_date":" 03/31/2026","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2024-01-24"},{"id":"f98339f3-8da6-4706-ab29-7a338e6db7fa","acronym":"TTI-622-01","url":"https://clinicaltrials.gov/study/NCT03530683","created_at":"2021-07-15T16:53:02.099Z","updated_at":"2024-07-02T16:35:25.423Z","phase":"Phase 1","brief_title":"A Clinical Trial to Learn About the Study Medicine Called Maplirpacept (PF-07901801), Alone and When Used in Combination With Other Medicines to Treat Participants With Advanced Hematological Malignancies, Including Lymphoma, Leukemia and Multiple Myeloma","source_id_and_acronym":"NCT03530683 - TTI-622-01","lead_sponsor":"Pfizer","biomarkers":" TP53","pipe":" | ","alterations":" TP53 mutation • TP53 wild-type","tags":["TP53"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • TP53 wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • Rituxan (rituximab) • azacitidine • carfilzomib • dexamethasone • Sarclisa (isatuximab-irfc) • dexamethasone injection • maplirpacept (TTI-622)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 177","initiation":"Initiation: 06/07/2018","start_date":" 06/07/2018","primary_txt":" Primary completion: 09/11/2024","primary_completion_date":" 09/11/2024","study_txt":" Completion: 09/11/2024","study_completion_date":" 09/11/2024","last_update_posted":"2023-12-22"},{"id":"4c303da3-0333-482c-a447-3a810066c7aa","acronym":"AMBUSH","url":"https://clinicaltrials.gov/study/NCT05514990","created_at":"2023-11-18T23:15:37.982Z","updated_at":"2024-07-02T16:35:28.859Z","phase":"Phase 1/2","brief_title":"Bortezomib and Pembrolizumab With or Without Pelareorep for the Treatment of Relapsed or Refractory Multiple Myeloma, AMBUSH Trial","source_id_and_acronym":"NCT05514990 - AMBUSH","lead_sponsor":"University of Southern California","biomarkers":" CD8 • PD-1 • IFNG • CD4 • GZMB","pipe":" | ","alterations":" PD-L1 expression","tags":["CD8 • PD-1 • IFNG • CD4 • GZMB"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • bortezomib • Reolysin (pelareorep) • Hemady (dexamethasone tablets) • dexamethasone injection"],"overall_status":"Recruiting","enrollment":" Enrollment 42","initiation":"Initiation: 10/07/2022","start_date":" 10/07/2022","primary_txt":" Primary completion: 10/07/2025","primary_completion_date":" 10/07/2025","study_txt":" Completion: 10/07/2026","study_completion_date":" 10/07/2026","last_update_posted":"2023-11-17"},{"id":"a7b10d24-6834-4ab0-b432-bed5ee7f3e42","acronym":"","url":"https://clinicaltrials.gov/study/NCT06062641","created_at":"2023-10-02T20:12:32.544Z","updated_at":"2024-07-02T16:35:30.152Z","phase":"Phase 2","brief_title":"Selinexor Combined With R-GDP Regimen for TP53-altered R/R DLBCL","source_id_and_acronym":"NCT06062641","lead_sponsor":"Ruijin Hospital","biomarkers":" TP53","pipe":" | ","alterations":" TP53 mutation • TP53 deletion","tags":["TP53"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • TP53 deletion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • Xpovio (selinexor) • dexamethasone injection"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 10/30/2023","start_date":" 10/30/2023","primary_txt":" Primary completion: 04/30/2024","primary_completion_date":" 04/30/2024","study_txt":" Completion: 09/30/2027","study_completion_date":" 09/30/2027","last_update_posted":"2023-11-07"},{"id":"f300739e-1f9e-42ac-8361-e1fbf968624a","acronym":"PhALLCON","url":"https://clinicaltrials.gov/study/NCT03589326","created_at":"2021-01-18T17:39:06.668Z","updated_at":"2024-07-02T16:35:31.409Z","phase":"Phase 3","brief_title":"A Study of Ponatinib Versus Imatinib in Adults With Acute Lymphoblastic Leukemia","source_id_and_acronym":"NCT03589326 - PhALLCON","lead_sponsor":"Takeda","biomarkers":" ABL1 • BCR","pipe":"","alterations":" ","tags":["ABL1 • BCR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e imatinib • cytarabine • Iclusig (ponatinib) • vincristine • prednisone • dexamethasone • dexamethasone injection • methotrexate IV"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 245","initiation":"Initiation: 10/04/2018","start_date":" 10/04/2018","primary_txt":" Primary completion: 08/12/2022","primary_completion_date":" 08/12/2022","study_txt":" Completion: 07/31/2027","study_completion_date":" 07/31/2027","last_update_posted":"2023-10-27"},{"id":"6a2118f7-f4ed-47ee-b68b-d30be8e0cf00","acronym":"BelaRd","url":"https://clinicaltrials.gov/study/NCT04808037","created_at":"2021-03-19T15:59:18.313Z","updated_at":"2025-02-25T13:20:01.120Z","phase":"Phase 1/2","brief_title":"Blmf, Lenalidomide and Dexamethasone in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma","source_id_and_acronym":"NCT04808037 - BelaRd","lead_sponsor":"Hellenic Society of Hematology","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lenalidomide • dexamethasone • Blenrep (belantamab mafodotin-blmf) • dexamethasone injection"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 66","initiation":"Initiation: 02/22/2021","start_date":" 02/22/2021","primary_txt":" Primary completion: 09/08/2028","primary_completion_date":" 09/08/2028","study_txt":" Completion: 11/08/2028","study_completion_date":" 11/08/2028","last_update_posted":"2023-10-24"},{"id":"983fc00c-e4fa-4493-ab00-ce5acc8c3755","acronym":"HEM-iSMART B","url":"https://clinicaltrials.gov/study/NCT05751044","created_at":"2023-03-02T15:01:24.701Z","updated_at":"2024-07-02T16:35:51.002Z","phase":"Phase 1/2","brief_title":"HEM-iSMART-B: Dasatinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies","source_id_and_acronym":"NCT05751044 - HEM-iSMART B","lead_sponsor":"Princess Maxima Center for Pediatric Oncology","biomarkers":" ABL1 • ETV6 • NUP214 • SATB1","pipe":" | ","alterations":" NUP214-ABL1 fusion • ABL1 fusion","tags":["ABL1 • ETV6 • NUP214 • SATB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NUP214-ABL1 fusion • ABL1 fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • dasatinib • cytarabine • cyclophosphamide • dexamethasone • dexamethasone injection"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 26","initiation":"Initiation: 10/01/2023","start_date":" 10/01/2023","primary_txt":" Primary completion: 10/01/2030","primary_completion_date":" 10/01/2030","study_txt":" Completion: 10/01/2030","study_completion_date":" 10/01/2030","last_update_posted":"2023-04-10"},{"id":"c38bf8bf-b726-4684-ac2b-3f7adfe5aeb0","acronym":"","url":"https://clinicaltrials.gov/study/NCT01242267","created_at":"2021-01-18T05:00:11.712Z","updated_at":"2025-02-25T14:56:08.019Z","phase":"Phase 1/2","brief_title":"Escalating Doses of Thalidomide in Conjunction With Bortezomib and HIgh Dose Melphalan for BSCT","source_id_and_acronym":"NCT01242267","lead_sponsor":"Hackensack Meridian Health","biomarkers":" BCL2 • CD34","pipe":"","alterations":" ","tags":["BCL2 • CD34"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e bortezomib • thalidomide • melphalan • dexamethasone injection"],"overall_status":"Completed","enrollment":" Enrollment 29","initiation":"Initiation: 05/11/2010","start_date":" 05/11/2010","primary_txt":" Primary completion: 01/20/2016","primary_completion_date":" 01/20/2016","study_txt":" Completion: 01/20/2016","study_completion_date":" 01/20/2016","last_update_posted":"2023-01-02"},{"id":"3a0c49c1-727b-492b-bc54-7034bb716618","acronym":"KMM1911","url":"https://clinicaltrials.gov/study/NCT05497102","created_at":"2022-08-15T11:10:45.029Z","updated_at":"2024-07-02T16:36:05.577Z","phase":"Phase 2","brief_title":"Carfilzomib, Lenalidomide, and Dexamethasone Re-induction Followed by the 2nd ASCT in Multiple Myeloma Patients Relapsed After the 1st ASCT","source_id_and_acronym":"NCT05497102 - KMM1911","lead_sponsor":"Samsung Medical Center","biomarkers":" CD34","pipe":"","alterations":" ","tags":["CD34"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lenalidomide • carfilzomib • dexamethasone • dexamethasone injection"],"overall_status":"Recruiting","enrollment":" Enrollment 58","initiation":"Initiation: 11/08/2021","start_date":" 11/08/2021","primary_txt":" Primary completion: 05/01/2024","primary_completion_date":" 05/01/2024","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2022-08-12"},{"id":"913fc7d5-b877-40bc-b207-b6d04af975f5","acronym":"","url":"https://clinicaltrials.gov/study/NCT04624958","created_at":"2021-01-19T20:35:20.227Z","updated_at":"2024-07-02T16:36:10.768Z","phase":"Phase 2","brief_title":"Zanubrutinib and Rituximab Followed by R-DHAOx Then Maintenance With Zanubrutinib for Newly-Diagnosed MCL","source_id_and_acronym":"NCT04624958","lead_sponsor":"Sun Yat-sen University","biomarkers":" TP53 • MYC • CD20","pipe":" | ","alterations":" TP53 mutation • CD20 positive","tags":["TP53 • MYC • CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • CD20 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • cytarabine • oxaliplatin • Brukinsa (zanubrutinib) • dexamethasone injection"],"overall_status":"Recruiting","enrollment":" Enrollment 42","initiation":"Initiation: 12/01/2020","start_date":" 12/01/2020","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2022-05-09"}]